Cellectis S.A. Logo

Cellectis S.A.

CMVLF

(0.0)
Stock Price

2,54 USD

-19.93% ROA

-75.49% ROE

-2.83x PER

Market Cap.

183.117.744,00 USD

48.33% DER

0% Yield

-294.25% NPM

Cellectis S.A. Stock Analysis

Cellectis S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cellectis S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Cellectis S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cellectis S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Cellectis S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cellectis S.A. Revenue
Year Revenue Growth
2007 4.101.360
2008 14.770.164 72.23%
2009 17.319.044 14.72%
2010 20.980.183 17.45%
2011 20.728.403 -1.21%
2012 27.814.954 25.48%
2013 22.816.150 -21.91%
2014 26.298.701 13.24%
2015 55.043.404 52.22%
2016 42.584.451 -29.26%
2017 25.188.000 -69.07%
2018 12.731.000 -97.85%
2019 15.190.000 16.19%
2020 73.949.000 79.46%
2021 73.949.000 0%
2022 19.171.000 -285.73%
2023 620.000 -2992.1%
2023 770.799 19.56%
2024 32.081.732 97.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cellectis S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 11.420.425 100%
2010 16.373.187 30.25%
2011 15.949.711 -2.66%
2012 25.102.494 36.46%
2013 34.440.332 27.11%
2014 17.519.091 -96.59%
2015 57.299.980 69.43%
2016 74.564.595 23.15%
2017 79.227.000 5.88%
2018 76.567.000 -3.47%
2019 92.042.000 16.81%
2020 86.950.000 -5.86%
2021 86.950.000 0%
2022 97.501.000 10.82%
2023 75.576.000 -29.01%
2023 89.480.158 15.54%
2024 93.598.588 4.4%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cellectis S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 4.277.778
2008 5.703.427 25%
2009 7.971.803 28.45%
2010 0 0%
2011 0 0%
2012 25.825.905 100%
2013 30.489.657 15.3%
2014 15.945.571 -91.21%
2015 29.778.278 46.45%
2016 41.258.255 27.82%
2017 44.750.000 7.8%
2018 47.247.000 5.28%
2019 43.017.000 -9.83%
2020 44.201.000 2.68%
2021 37.869.000 -16.72%
2022 17.494.000 -116.47%
2023 6.228.000 -180.89%
2023 16.812.000 62.96%
2024 15.524.000 -8.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cellectis S.A. EBITDA
Year EBITDA Growth
2007 -6.088.617
2008 -3.185.121 -91.16%
2009 -10.241.275 68.9%
2010 -12.980.450 21.1%
2011 -24.502.625 47.02%
2012 -26.139.339 6.26%
2013 1.170.979 2332.26%
2014 -4.433.581 126.41%
2015 -28.620.471 84.51%
2016 -63.960.288 55.25%
2017 -92.649.000 30.96%
2018 -105.091.000 11.84%
2019 -123.552.000 14.94%
2020 -85.437.000 -44.61%
2021 -85.437.000 0%
2022 -89.666.000 4.72%
2023 -66.232.000 -35.38%
2023 -89.946.719 26.37%
2024 -76.650.288 -17.35%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cellectis S.A. Gross Profit
Year Gross Profit Growth
2007 2.624.404
2008 13.227.719 80.16%
2009 14.993.696 11.78%
2010 19.058.385 21.33%
2011 17.468.731 -9.1%
2012 25.784.907 32.25%
2013 21.968.295 -17.37%
2014 22.608.104 2.83%
2015 52.337.481 56.8%
2016 40.896.470 -27.98%
2017 22.568.000 -81.21%
2018 9.992.000 -125.86%
2019 3.798.000 -163.09%
2020 37.674.000 89.92%
2021 37.674.000 0%
2022 17.399.000 -116.53%
2023 -104.000 16829.81%
2023 -18.855.499 99.45%
2024 13.264.908 242.15%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cellectis S.A. Net Profit
Year Net Profit Growth
2007 -4.356.511
2008 171.228 2644.27%
2009 -5.518.941 103.1%
2010 -10.723.500 48.53%
2011 -30.896.248 65.29%
2012 -29.452.218 -4.9%
2013 -84.278.770 65.05%
2014 24.320 346641%
2015 -22.460.805 100.11%
2016 -63.918.220 64.86%
2017 -99.368.000 35.68%
2018 -78.693.000 -26.27%
2019 -102.091.000 22.92%
2020 -81.074.000 -25.92%
2021 -81.074.000 0%
2022 -106.139.000 23.62%
2023 -69.928.000 -51.78%
2023 -103.173.851 32.22%
2024 -100.571.320 -2.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cellectis S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 -2 100%
2012 -1 -100%
2013 -4 75%
2014 0 0%
2015 -1 0%
2016 -2 100%
2017 -3 50%
2018 -2 -100%
2019 -2 50%
2020 -2 -100%
2021 -2 0%
2022 -2 50%
2023 -1 -100%
2023 -2 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cellectis S.A. Free Cashflow
Year Free Cashflow Growth
2007 -5.769.315
2008 988.389 683.71%
2009 -7.762.622 112.73%
2010 -27.757.681 72.03%
2011 -17.438.922 -59.17%
2012 -31.596.001 44.81%
2013 -27.542.876 -14.72%
2014 50.307.650 154.75%
2015 -715.020 7135.84%
2016 -44.424.930 98.39%
2017 -54.983.000 19.2%
2018 -73.023.000 24.7%
2019 -82.100.000 11.06%
2020 -126.522.000 35.11%
2021 -124.305.000 -1.78%
2022 -89.885.000 -38.29%
2023 -17.408.000 -416.34%
2023 -26.699.279 34.8%
2024 50.459.739 152.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cellectis S.A. Operating Cashflow
Year Operating Cashflow Growth
2007 -5.622.057
2008 1.779.101 416.01%
2009 -7.049.115 125.24%
2010 -21.101.210 66.59%
2011 -13.191.627 -59.96%
2012 -26.110.244 49.48%
2013 -25.628.987 -1.88%
2014 50.738.119 150.51%
2015 3.537.926 -1334.12%
2016 -31.087.249 111.38%
2017 -52.327.000 40.59%
2018 -68.137.000 23.2%
2019 -69.142.000 1.45%
2020 -80.262.000 13.85%
2021 -104.562.000 23.24%
2022 -87.444.000 -19.58%
2023 -17.094.000 -411.55%
2023 -25.603.825 33.24%
2024 51.452.767 149.76%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cellectis S.A. Capital Expenditure
Year Capital Expenditure Growth
2007 147.258
2008 790.712 81.38%
2009 713.508 -10.82%
2010 6.656.470 89.28%
2011 4.247.294 -56.72%
2012 5.485.757 22.58%
2013 1.913.889 -186.63%
2014 430.468 -344.61%
2015 4.252.946 89.88%
2016 13.337.680 68.11%
2017 2.656.000 -402.17%
2018 4.886.000 45.64%
2019 12.958.000 62.29%
2020 46.260.000 71.99%
2021 19.743.000 -134.31%
2022 2.441.000 -708.81%
2023 314.000 -677.39%
2023 1.095.454 71.34%
2024 993.028 -10.31%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cellectis S.A. Equity
Year Equity Growth
2007 43.543.237
2008 46.210.708 5.77%
2009 73.220.528 36.89%
2010 50.127.676 -46.07%
2011 37.021.579 -35.4%
2012 81.685.930 54.68%
2013 6.650.279 -1128.31%
2014 72.385.572 90.81%
2015 288.215.292 74.88%
2016 274.046.106 -5.17%
2017 285.904.000 4.15%
2018 450.271.000 36.5%
2019 355.470.000 -26.67%
2020 308.846.000 -15.1%
2021 236.474.000 -30.6%
2022 125.941.000 -87.77%
2023 76.123.000 -65.44%
2023 84.625.229 10.05%
2024 148.522.643 43.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cellectis S.A. Assets
Year Assets Growth
2007 53.873.182
2008 60.831.918 11.44%
2009 91.339.045 33.4%
2010 69.231.280 -31.93%
2011 131.886.462 47.51%
2012 115.105.668 -14.58%
2013 44.113.341 -160.93%
2014 167.340.337 73.64%
2015 372.883.913 55.12%
2016 330.678.137 -12.76%
2017 332.882.000 0.66%
2018 500.840.000 33.54%
2019 467.469.000 -7.14%
2020 469.471.000 0.43%
2021 382.076.000 -22.87%
2022 261.216.000 -46.27%
2023 209.700.000 -24.57%
2023 333.994.631 37.21%
2024 406.907.669 17.92%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cellectis S.A. Liabilities
Year Liabilities Growth
2007 10.329.945
2008 14.621.210 29.35%
2009 18.118.516 19.3%
2010 19.103.604 5.16%
2011 94.864.882 79.86%
2012 33.419.737 -183.86%
2013 37.463.061 10.79%
2014 94.954.764 60.55%
2015 84.668.620 -12.15%
2016 56.632.030 -49.51%
2017 46.978.000 -20.55%
2018 50.569.000 7.1%
2019 111.999.000 54.85%
2020 160.625.000 30.27%
2021 145.602.000 -10.32%
2022 135.275.000 -7.63%
2023 133.577.000 -1.27%
2023 249.369.402 46.43%
2024 258.385.025 3.49%

Cellectis S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.14
Net Income per Share
-0.9
Price to Earning Ratio
-2.83x
Price To Sales Ratio
14.12x
POCF Ratio
4.46
PFCF Ratio
3.69
Price to Book Ratio
1.54
EV to Sales
11.13
EV Over EBITDA
-1.8
EV to Operating CashFlow
2.81
EV to FreeCashFlow
2.91
Earnings Yield
-0.35
FreeCashFlow Yield
0.27
Market Cap
0,18 Bil.
Enterprise Value
0,14 Bil.
Graham Number
5.76
Graham NetNet
0.38

Income Statement Metrics

Net Income per Share
-0.9
Income Quality
-0.51
ROE
-0.81
Return On Assets
-0.22
Return On Capital Employed
-0.34
Net Income per EBT
0.8
EBT Per Ebit
1.35
Ebit per Revenue
-2.71
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
1.17
Research & Developement to Revenue
6.99
Stock Based Compensation to Revenue
0.28
Gross Profit Margin
1.04
Operating Profit Margin
-2.71
Pretax Profit Margin
-3.67
Net Profit Margin
-2.94

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.57
Free CashFlow per Share
0.55
Capex to Operating CashFlow
0.04
Capex to Revenue
0.14
Capex to Depreciation
0.1
Return on Invested Capital
-0.43
Return on Tangible Assets
-0.2
Days Sales Outstanding
741.34
Days Payables Outstanding
445.56
Days of Inventory on Hand
0
Receivables Turnover
0.49
Payables Turnover
0.82
Inventory Turnover
14911171
Capex per Share
0.02

Balance Sheet

Cash per Share
3,02
Book Value per Share
1,65
Tangible Book Value per Share
1.64
Shareholders Equity per Share
1.65
Interest Debt per Share
0.87
Debt to Equity
0.48
Debt to Assets
0.18
Net Debt to EBITDA
0.48
Current Ratio
1.92
Tangible Asset Value
0,15 Bil.
Net Current Asset Value
0,05 Bil.
Invested Capital
230728676
Working Capital
0,15 Bil.
Intangibles to Total Assets
0
Average Receivables
0,03 Bil.
Average Payables
0,02 Bil.
Average Inventory
0.5
Debt to Market Cap
0.39

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cellectis S.A. Dividends
Year Dividends Growth

Cellectis S.A. Profile

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

CEO
Dr. Andre Choulika Ph.D.
Employee
216
Address
8, rue de la Croix Jarry
Paris, 75013

Cellectis S.A. Executives & BODs

Cellectis S.A. Executives & BODs
# Name Age
1 Dr. David j. d. Sourdive Ph.D.
Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director
70
2 Mr. Jean Charles Epinat
Chief Technological Officer
70
3 Ms. Marie-Bleuenn Terrier
General Counsel & Secretary of the Board of Directors
70
4 Mr. Stephan Reynier M.Sc.
Chief Regulatory & Pharmaceutical Compliance Officer
70
5 Pascalyne Wilson
Director of Communications
70
6 Mr. Arthur Stril
Interim Chief Financial Officer
70
7 Ms. Kyung Nam-Wortman
Executive Vice President & Chief Human Resources Officer
70
8 Dr. Philippe Duchateau Ph.D.
Chief Scientific Officer
70
9 Valerie Cros
Principal Financial Officer & Principal Accounting Officer
70
10 Dr. Andre Choulika Ph.D.
Co-Founder, Chief Executive Officer & Director
70

Cellectis S.A. Competitors